We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

6 hedge funds and large institutions have $373K invested in Benitec Biopharma in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

96% more capital invested

Capital invested by funds: $190K → $373K (+$183K)

0% more funds holding

Funds holding: 6 → 6 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$120K
2
Morgan Stanley
Morgan Stanley
New York
+$70.7K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2.53K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$166K +$120K +143 +186%
Morgan Stanley
2
Morgan Stanley
New York
$134K +$70.7K +84 +104%
Renaissance Technologies
3
Renaissance Technologies
New York
$44K – – –
UBS Group
4
UBS Group
Switzerland
$11K -$2.53K -3 -18%
CIBC Private Wealth Group
5
CIBC Private Wealth Group
Georgia
$10K – – –
Bank of America
6
Bank of America
North Carolina
$8K – – –

BNTC Hedge Fund Activity: Q1 2018 in Review

6 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2018, worth a combined $373K — up 96% from $190K a quarter earlier.

Fund positioning in BNTC was balanced in Q1 2018: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $120K. The largest seller was UBS Group, cutting an estimated $2.53K.

  • 6 institutional investors held Benitec Biopharma (BNTC) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $373K of Benitec Biopharma stock for Q1 2018, up 96% quarter-over-quarter.
  • 0 funds opened new Benitec Biopharma positions in Q1 2018 and 0 closed out.
  • The largest Benitec Biopharma buyer in Q1 2018 was Susquehanna International Group, an estimated $120K added.
  • The largest Benitec Biopharma seller in Q1 2018 was UBS Group, an estimated $2.53K sold.

Based on aggregated 13F filings for Q1 2018.